Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
Provided By GlobeNewswire
Last update: Jan 13, 2025
Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025
Read more at globenewswire.com3.44
+0.59 (+20.7%)
Find more stocks in the Stock Screener
ELDN Latest News and Analysis
